DermaGen develops peptide therapeutics for topical use based on novel and proprietary antimicrobial peptides (AMPs). We intend to be a leading R&D company in this area with the aim of offering innovative and profitable licensing opportunities to selected pharmaceutical companies with significant market potential. DermaGen focuses on R&D to provide new and patented products initially for dermatological indications. DermaGen has selected its first candidate drug (CD), which has entered the development phase. To help advance development of our product portfolio and to bring them to market, we welcome the interest of new investors, partners and collaborators.